Combination Therapy with Ruxolitinib and Hydroxyurea for the Treatment of Myeloid-Predominant Leukocytosis in a Patient with Myelofibrosis.

Combination Therapy with Ruxolitinib and Hydroxyurea for the Treatment of Myeloid-Predominant Leukocytosis in a Patient with Myelofibrosis. Acta Haematol. 2018 Mar 29;139(3):164-165 Authors: Caocci G, Ghiani S, Mocci C, La Nasa G PMID: 29597187 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29597187?dopt=Abstract

Source: Acta Haematologica - March 29, 2018 Category: Hematology Authors: Caocci G, Ghiani S, Mocci C, La Nasa G Tags: Acta Haematol Source Type: research

More News: Hematology